With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 1, 2017. A pooled analysis in JCO of patient data from 16 trials of concurrent chemoradiation for stage III NSCLC reports that, despite having similar PFS, older (>70) patients had worse survival, more toxicity, and more grade 5 toxicity with chemoradiation than younger patients. It's no big surprise our assessment of patient fitness for current lung cancer treatment regimens could use some work. Sounds like advanced NSCLC could use a trial like this one in GBM randomizing older patients to aggressive versus conservative treatment.